サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1584134

肺腺がん治療市場：薬剤クラス別、治療タイプ別、治療ステージ別、エンドユーザー別、国別、地域別 - 産業分析、市場規模、市場シェア、2024-2032年予測

Lung Adenocarcinoma Treatment Market, By Drug Class, By Therapy Type, By Stage of Treatment, By End-User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

出版日
ページ情報
英文 303 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
肺腺がん治療市場：薬剤クラス別、治療タイプ別、治療ステージ別、エンドユーザー別、国別、地域別 - 産業分析、市場規模、市場シェア、2024-2032年予測
出版日: 2024年11月04日
発行: AnalystView Market Insights
ページ情報: 英文 303 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

レポートハイライト

肺腺がん治療市場規模は2023年に55億1,209万米ドルとなり、2024年から2032年にかけて10.70%のCAGRで拡大

肺腺がん治療市場-市場力学

喫煙率の上昇が肺腺がん治療市場の成長を促進

喫煙は肺がんの主要な危険因子であるため、世界の喫煙率の上昇が肺腺がん治療市場の成長に大きく寄与しています。世界保健機関（WHO）の推計によると、現在13億人以上が喫煙者であり、タバコの使用は世界のがん関連死亡の約22％を占めています。米国では、疾病対策予防センター（CDC）の報告によると、肺がんはがん死亡の主な原因であり、その約85％が喫煙によるものです。国民の意識向上キャンペーンが高まり、禁煙プログラムが実施されるにつれて、効果的な治療法に対する需要が高まると予想されます。製薬会社は、患者数の増加に対応するため、標的治療や免疫療法などの革新的な治療に投資することでこの傾向に対応しています。さらに、米国肺協会のような組織によるイニシアチブは、喫煙率の低下と早期診断の改善を目指しており、肺腺がん分野における高度な治療オプションの必要性をさらに高めています。

肺腺がん治療市場-主要インサイト

当社のリサーチアナリストが共有した分析によると、世界市場は予測期間（2024-2032年）に約10.70％のCAGRで毎年成長すると推定されます。

薬剤クラス別では、EGFR阻害剤が2023年に最大の市場シェアを示すと予測されます。

治療タイプ別では、2023年には標的療法が主要なタイプとなっています。

治療ステージ別では、進行性または転移性腺がんが2023年の主要タイプでした。

地域別では、北米が2023年の主要収益源でした。

肺腺がん治療市場-セグメンテーション分析：

世界の肺腺がん治療市場は、薬剤クラス別、治療タイプ別、治療ステージ別、エンドユーザー別、地域別に区分されます。

薬剤クラス別に市場は4つに分類される：EGFR阻害剤、ALK阻害剤、PD-1/PD-L1阻害剤、VEGF阻害剤です。EGFR阻害剤は、特定の変異を標的とする有効性により、最優先されます。続いてALK阻害剤がALK陽性患者に標的治療を提供し、PD-1/PD-L1阻害剤とVEGF阻害剤がさらなる治療選択肢を提供します。

市場は治療法の種類によって4つのカテゴリーに分けられる：すなわち、化学療法、標的療法、免疫療法、併用療法です。標的療法は、特定のがん変異に正確に対処できることから、最も高い評価を得ています。免疫療法は免疫システムを活用してがんと闘う。化学療法は依然として標準的であるが、優先順位は低いです。

肺腺がん治療市場-地理的洞察

北米は肺腺がん治療市場の主要地域であるが、その主な理由は肺がんの罹患率の高さとヘルスケアのインフラの先進性です。米国がん協会によると、2023年には米国におけるがん死亡者数の約25%を肺がんが占めると予想されています。2022年、米国食品医薬品局（FDA）は進行肺腺がん患者に対するニボルマブとイピリムマブの新しい併用療法を承認し、治療選択肢の革新が進んでいることを強調しました。ドイツや英国などの国々が肺がん研究や個別化医療アプローチへの投資を増やしており、欧州もこれに追随しています。欧州腫瘍学会（European Society for Medical Oncology：ESMO）は、早期発見と予防を目的としたイニシアチブに支えられ、標的療法に重点が置かれるようになっていると報告しています。一方、アジア太平洋地域は、喫煙率の上昇とヘルスケア支出の増加により、重要な市場として浮上しており、現地企業と世界的製薬企業とのコラボレーションにより、地域全体で革新的治療へのアクセスが容易になっています。

肺腺がん治療市場-競合情勢：

肺腺がん治療市場の競合情勢は、高度な医療インフラと肺がん有病率の高さにより市場シェアをリードする北米の主要企業による活発な活動が特徴です。2023年には、RocheやAstraZenecaなどの大手製薬企業が、標的療法や免疫療法の開発を強化するための提携を発表しました。例えば、アストラゼネカが発売した新薬タグリッソ（オシメルチニブ）は、EGFR変異肺腺がん患者の治療で有望視されており、腫瘍内科医の間で好んで使用されています。さらに、ブリストル・マイヤーズスクイブ社が2020年後半にマイオカルディア社を買収したことで、肺がん治療薬を中心とした腫瘍学ポートフォリオの強化が可能になった。欧州企業も躍進しており、最近ではノバルティスと欧州がん機構が革新的治療への患者アクセスを改善するために提携しました。競合が激化する中、現在進行中の臨床試験と製品革新は引き続き重要であり、世界の肺腺がん治療の選択肢の将来の情勢を形成しています。

目次

第1章 肺腺がん治療市場概要

  • 調査範囲
  • 市場推定年

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 肺腺がん治療の主要市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の将来動向

第4章 肺腺がん治療産業研究

  • PEST分析
  • ポーターのファイブフォース分析
  • 成長見通しマッピング
  • 規制枠組み分析

第5章 肺腺がん治療市場： COVID-19の影響分析

  • COVID-19以前の影響分析
  • COVID-19後の影響分析

第6章 肺腺がん治療市場情勢

  • 肺腺がん治療市場シェア分析、2023年
  • 主要メーカー別内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 肺腺がん治療市場-薬剤クラス別

  • 概要
    • 薬剤クラス別セグメントシェア分析
    • EGFR阻害剤
    • ALK阻害剤
    • PD-1/PD-L1阻害剤
    • VEGF阻害剤

第8章 肺腺がん治療市場- 治療タイプ別

  • 概要
    • 治療タイプ別セグメントシェア分析
    • 化学療法
    • 標的療法
    • 免疫療法
    • 併用療法

第9章 肺腺がん治療市場-治療ステージ別

  • 概要
    • 治療ステージ別セグメントシェア分析
    • 早期腺がん
    • 進行性または転移性腺がん

第10章 肺腺がん治療市場- エンドユーザー別

  • 概要
    • エンドユーザー別セグメントシェア分析
    • 病院
    • 腫瘍科クリニック
    • 調査機関

第11章 肺腺がん治療市場-地域別

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • イタリア
    • 英国
    • フランス
    • ロシア
    • オランダ
    • スウェーデン
    • ポーランド
    • その他
  • アジア太平洋（APAC）
    • 概要
    • アジア太平洋地域の主要メーカー
    • インド
    • 中国
    • 日本
    • 韓国
    • オーストラリア
    • タイ
    • インドネシア
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東およびアフリカ
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第12章 主要ベンダー分析- 肺腺がん治療業界

  • 競合ダッシュボード
  • 企業プロファイル
    • Amgen Inc.
    • Astellas Pharma Inc.
    • AstraZeneca PLC
    • Bayer AG
    • Boehringer Ingelheim GmbH
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • Genentech, Inc.（Roche）
    • Gilead Sciences, Inc.
    • GlaxoSmithKline plc
    • Janssen Pharmaceuticals, Inc.
    • Merck &Co., Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi SA
    • Takeda Pharmaceutical Company Limited
    • Others

第13章 アナリストの全方位展望

目次
Product Code: ANV4114

REPORT HIGHLIGHT

Lung Adenocarcinoma Treatment Market size was valued at USD 5,512.09 Million in 2023, expanding at a CAGR of 10.70% from 2024 to 2032.

The Lung Adenocarcinoma Treatment Market encompasses therapies specifically aimed at treating lung adenocarcinoma, a common subtype of non-small cell lung cancer. With rising global incidences, attributed to increased smoking rates and environmental factors, the market is witnessing significant growth. According to the American Cancer Society, approximately 236,000 new cases of lung cancer are expected in the U.S. in 2023, with adenocarcinoma accounting for nearly 40% of those cases. Advances in targeted therapies, such as epidermal growth factor receptor (EGFR) inhibitors and anaplastic lymphoma kinase (ALK) inhibitors, are enhancing treatment options, while immunotherapy is gaining traction for its effectiveness in advanced stages. However, challenges such as high treatment costs and adverse side effects may hinder market expansion. Nevertheless, ongoing research and development initiatives aimed at improving existing therapies and the emergence of personalized medicine present substantial opportunities for market players, fostering innovations that could transform patient outcomes in lung adenocarcinoma treatment.

Lung Adenocarcinoma Treatment Market- Market Dynamics

Rising Smoking Rates Fuel Growth in the Lung Adenocarcinoma Treatment Market

The escalating rates of smoking worldwide significantly contribute to the growth of the Lung Adenocarcinoma Treatment Market, as smoking is a primary risk factor for lung cancer. The World Health Organization (WHO) estimates that over 1.3 billion people are currently smokers, with tobacco use accounting for nearly 22% of cancer-related deaths globally. In the United States, the Centers for Disease Control and Prevention (CDC) reports that lung cancer is the leading cause of cancer mortality, with smoking responsible for approximately 85% of cases. As public awareness campaigns increase and smoking cessation programs are implemented, the demand for effective treatments is anticipated to rise. Pharmaceutical companies are responding to this trend by investing in innovative therapies, including targeted treatments and immunotherapies, to address the growing patient population. Additionally, initiatives from organizations like the American Lung Association aim to reduce smoking prevalence and improve early diagnosis, further driving the need for advanced treatment options in the lung adenocarcinoma sector.

Lung Adenocarcinoma Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 10.70% over the forecast period (2024-2032)

Based on Drug Class segmentation, EGFR Inhibitors were predicted to show maximum market share in the year 2023

Based on Therapy Type segmentation, Targeted Therapy was the leading type in 2023

Based on Stage of Treatment segmentation, Advanced or Metastatic Adenocarcinoma was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Lung Adenocarcinoma Treatment Market- Segmentation Analysis:

The Global Lung Adenocarcinoma Treatment Market is segmented on the basis of Drug Class, Therapy Type, Stage of Treatment, End-User, and Region.

The market is divided into four categories based on Drug Class: EGFR Inhibitors, ALK Inhibitors, PD-1/PD-L1 Inhibitors, and VEGF Inhibitors. EGFR Inhibitors hold the highest priority due to their effectiveness in targeting specific mutations. ALK Inhibitors follow, offering targeted therapy for ALK-positive patients, while PD-1/PD-L1 Inhibitors and VEGF Inhibitors provide additional treatment options.

The market is divided into four categories based on Therapy Type: Chemotherapy, Targeted Therapy, Immunotherapy, and Combination Therapy. Targeted therapy ranks highest due to its precision in addressing specific cancer mutations. Immunotherapy follows, leveraging the immune system to combat cancer. Combination therapy is gaining traction, while chemotherapy remains a standard but less prioritized option.

Lung Adenocarcinoma Treatment Market- Geographical Insights

North America is a leading region in the Lung Adenocarcinoma Treatment Market, primarily due to high incidences of lung cancer and advanced healthcare infrastructure. According to the American Cancer Society, lung cancer is expected to account for about 25% of all cancer deaths in the U.S. in 2023. In 2022, the U.S. Food and Drug Administration (FDA) approved a new combination therapy of nivolumab and ipilimumab for patients with advanced lung adenocarcinoma, highlighting the ongoing innovation in treatment options. Europe follows closely, with countries like Germany and the UK increasing investment in lung cancer research and personalized medicine approaches. The European Society for Medical Oncology (ESMO) reports a growing emphasis on targeted therapies, supported by initiatives aimed at early detection and prevention. Meanwhile, Asia-Pacific is emerging as a significant market due to rising smoking rates and increasing healthcare expenditure, with collaborations between local firms and global pharmaceutical companies facilitating access to innovative treatments across the region.

Lung Adenocarcinoma Treatment Market- Competitive Landscape:

The competitive landscape of the Lung Adenocarcinoma Treatment Market is characterized by significant activities from key players in North America, which leads in market share due to advanced healthcare infrastructure and a high prevalence of lung cancer. In 2023, major pharmaceutical companies such as Roche and AstraZeneca announced collaborations to enhance the development of targeted therapies and immunotherapies. For instance, AstraZeneca's launch of its new drug, Tagrisso (osimertinib), has shown promise in treating patients with EGFR-mutated lung adenocarcinoma, making it a preferred choice among oncologists. Additionally, Bristol-Myers Squibb's acquisition of MyoKardia in late 2020 has enabled them to bolster their oncology portfolio, focusing on lung cancer therapies. European companies are also making strides, with a recent partnership between Novartis and the European Cancer Organization to improve patient access to innovative treatments. As competition intensifies, ongoing clinical trials and product innovations remain critical, shaping the future landscape of lung adenocarcinoma treatment options globally.

Recent Developments:

In April 2024, the FDA approved alectinib (Alecensa) as an adjuvant treatment for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) following tumor resection, with the condition confirmed by an FDA-approved test.

In March 2024, Pfizer Inc. announced the long-term follow-up results from the Phase 3 CROWN trial, which assessed the efficacy of LORBRENA (lorlatinib), a third-generation ALK inhibitor, against XALKORI (crizotinib) in patients with untreated advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL LUNG ADENOCARCINOMA TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Genentech, Inc. (Roche)
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Janssen Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Others

GLOBAL LUNG ADENOCARCINOMA TREATMENT MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

  • EGFR Inhibitors
  • ALK Inhibitors
  • PD-1/PD-L1 Inhibitors
  • VEGF Inhibitors

GLOBAL LUNG ADENOCARCINOMA TREATMENT MARKET, BY THERAPY TYPE- MARKET ANALYSIS, 2019 - 2032

  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
  • Combination Therapy

GLOBAL LUNG ADENOCARCINOMA TREATMENT MARKET, BY STAGE OF TREATMENT- MARKET ANALYSIS, 2019 - 2032

  • Early-Stage Adenocarcinoma
  • Advanced or Metastatic Adenocarcinoma

GLOBAL LUNG ADENOCARCINOMA TREATMENT MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Oncology Clinics
  • Research Institutions

GLOBAL LUNG ADENOCARCINOMA TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Lung Adenocarcinoma Treatment Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Lung Adenocarcinoma Treatment Market Snippet by Drug Class
    • 2.1.2. Lung Adenocarcinoma Treatment Market Snippet by Therapy Type
    • 2.1.3. Lung Adenocarcinoma Treatment Market Snippet by Stage of Treatment
    • 2.1.4. Lung Adenocarcinoma Treatment Market Snippet by End-User
    • 2.1.5. Lung Adenocarcinoma Treatment Market Snippet by Country
    • 2.1.6. Lung Adenocarcinoma Treatment Market Snippet by Region
  • 2.2. Competitive Insights

3. Lung Adenocarcinoma Treatment Key Market Trends

  • 3.1. Lung Adenocarcinoma Treatment Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Lung Adenocarcinoma Treatment Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Lung Adenocarcinoma Treatment Market Opportunities
  • 3.4. Lung Adenocarcinoma Treatment Market Future Trends

4. Lung Adenocarcinoma Treatment Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Lung Adenocarcinoma Treatment Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Lung Adenocarcinoma Treatment Market Landscape

  • 6.1. Lung Adenocarcinoma Treatment Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Lung Adenocarcinoma Treatment Market - By Drug Class

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Class, 2023 & 2032 (%)
    • 7.1.2. EGFR Inhibitors
    • 7.1.3. ALK Inhibitors
    • 7.1.4. PD-1/PD-L1 Inhibitors
    • 7.1.5. VEGF Inhibitors

8. Lung Adenocarcinoma Treatment Market - By Therapy Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Therapy Type, 2023 & 2032 (%)
    • 8.1.2. Chemotherapy
    • 8.1.3. Targeted Therapy
    • 8.1.4. Immunotherapy
    • 8.1.5. Combination Therapy

9. Lung Adenocarcinoma Treatment Market - By Stage of Treatment

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Stage of Treatment, 2023 & 2032 (%)
    • 9.1.2. Early-Stage Adenocarcinoma
    • 9.1.3. Advanced or Metastatic Adenocarcinoma

10. Lung Adenocarcinoma Treatment Market - By End-User

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By End-User, 2023 & 2032 (%)
    • 10.1.2. Hospitals
    • 10.1.3. Oncology Clinics
    • 10.1.4. Research Institutions

11. Lung Adenocarcinoma Treatment Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Lung Adenocarcinoma Treatment Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Lung Adenocarcinoma Treatment Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.9. Italy
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.9.4. Italy Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.9.5. Italy Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.3.9.6. Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.10. United Kingdom
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. United Kingdom Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.10.4. United Kingdom Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.10.5. United Kingdom Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.3.10.6. United Kingdom Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.11. France
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.11.4. France Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.11.5. France Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.3.11.6. France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.12. Russia
      • 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.2. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.12.3. Russia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Russia Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.13. Netherlands
      • 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.2. Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.13.3. Netherlands Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.13.4. Netherlands Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.3.13.5. Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.2. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.15. Poland
      • 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.2. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.15.3. Poland Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Poland Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.16. Rest of Europe
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Rest of the Europe Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Rest of the Europe Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Lung Adenocarcinoma Treatment Key Manufacturers in Asia Pacific
    • 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. Asia Pacific Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.4.5. Asia Pacific Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
    • 11.4.6. Asia Pacific Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
    • 11.4.7. Asia Pacific Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.8. India
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.8.4. India Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.8.5. India Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.4.8.6. India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.9. China
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.9.4. China Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.9.5. China Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.4.9.6. China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.13. Thailand
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Thailand Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Thailand Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.14. Indonesia
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Indonesia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Indonesia Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.5. Latin America
    • 11.5.1. Overview
    • 11.5.2. Lung Adenocarcinoma Treatment Key Manufacturers in Latin America
    • 11.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. Latin America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.5.5. Latin America Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
    • 11.5.6. Latin America Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
    • 11.5.7. Latin America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa
    • 11.6.1. Overview
    • 11.6.2. Lung Adenocarcinoma Treatment Key Manufacturers in Middle East and Africa
    • 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.6.5. Middle East and Africa Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
    • 11.6.6. Middle East and Africa Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
    • 11.6.7. Middle East and Africa Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Stage of Treatment, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Lung Adenocarcinoma Treatment Industry

  • 12.1. Competitive Dashboard
  • 12.2. Company Profiles
    • 12.2.1. Amgen Inc.
    • 12.2.2. Astellas Pharma Inc.
    • 12.2.3. AstraZeneca PLC
    • 12.2.4. Bayer AG
    • 12.2.5. Boehringer Ingelheim GmbH
    • 12.2.6. Bristol-Myers Squibb Company
    • 12.2.7. Eli Lilly and Company
    • 12.2.8. Genentech, Inc. (Roche)
    • 12.2.9. Gilead Sciences, Inc.
    • 12.2.10. GlaxoSmithKline plc
    • 12.2.11. Janssen Pharmaceuticals, Inc.
    • 12.2.12. Merck & Co., Inc.
    • 12.2.13. Novartis AG
    • 12.2.14. Pfizer Inc.
    • 12.2.15. Sanofi S.A.
    • 12.2.16. Takeda Pharmaceutical Company Limited
    • 12.2.17. Others

13. 360 Degree Analyst View

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us